These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 25462267)

  • 21. Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting
    Abdel-Maksoud MS; Ali EMH; Ammar UM; Mersal KI; Yoo KH; Oh CH
    Bioorg Med Chem; 2020 Jun; 28(11):115493. PubMed ID: 32340792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAF
    Wang Y; Wan S; Li Z; Fu Y; Wang G; Zhang J; Wu X
    Eur J Med Chem; 2018 Jul; 155():210-228. PubMed ID: 29886324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, biological evaluation and 3D-QSAR studies of novel 4,5-dihydro-1H-pyrazole niacinamide derivatives as BRAF inhibitors.
    Li CY; Li QS; Yan L; Sun XG; Wei R; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 Jun; 20(12):3746-55. PubMed ID: 22583669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.
    Vasbinder MM; Aquila B; Augustin M; Chen H; Cheung T; Cook D; Drew L; Fauber BP; Glossop S; Grondine M; Hennessy E; Johannes J; Lee S; Lyne P; Mörtl M; Omer C; Palakurthi S; Pontz T; Read J; Sha L; Shen M; Steinbacher S; Wang H; Wu A; Ye M
    J Med Chem; 2013 Mar; 56(5):1996-2015. PubMed ID: 23398453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
    Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and biological evaluation of novel triaryl pyrazoline derivatives with dioxane moiety for selective BRAF
    Li HL; Su MM; Xu YJ; Xu C; Yang YS; Zhu HL
    Eur J Med Chem; 2018 Jul; 155():725-735. PubMed ID: 29940463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
    Kim YK; Ahn SK; Lee M
    Cancer Lett; 2012 Jul; 320(2):215-24. PubMed ID: 22425959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking.
    Ammar UM; Abdel-Maksoud MS; Mersal KI; Ali EMH; Yoo KH; Choi HS; Lee JK; Cha SY; Oh CH
    Bioorg Med Chem Lett; 2020 Oct; 30(20):127478. PubMed ID: 32781217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and biological evaluation of pyrazole derivatives containing acetamide bond as potential BRAF
    Wang CR; Wang ZF; Shi L; Wang ZC; Zhu HL
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2382-2390. PubMed ID: 29934244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and Biological Evaluation of Novel Type II B-Raf
    Wang PF; Wang ZF; Qiu HY; Huang Y; Hu HM; Wang ZC; Zhu HL
    ChemMedChem; 2018 Dec; 13(23):2558-2566. PubMed ID: 30353975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors.
    Li QS; Li CY; Lu X; Zhang H; Zhu HL
    Eur J Med Chem; 2012 Apr; 50():288-95. PubMed ID: 22361686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
    Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
    Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance.
    Wang L; Zhang Q; Zhu G; Zhang Z; Zhi Y; Zhang L; Mao T; Zhou X; Chen Y; Lu T; Tang W
    Eur J Med Chem; 2017 Apr; 130():86-106. PubMed ID: 28242553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Fluoro Derivative of Embelin, as Potent B-RAF Inhibitor in Melanoma.
    Babu A; Laila SP; Fernandez A
    Anticancer Agents Med Chem; 2021; 21(15):2066-2074. PubMed ID: 33372883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold.
    Abdel-Maksoud MS; Ammar UM; Oh CH
    Bioorg Med Chem; 2019 May; 27(10):2041-2051. PubMed ID: 30955995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of highly selective CRAF inhibitors, 3-carboxamido-2H-indazole-6-arylamide: In silico FBLD design, synthesis and evaluation.
    Aman W; Lee J; Kim M; Yang S; Jung H; Hah JM
    Bioorg Med Chem Lett; 2016 Feb; 26(4):1188-92. PubMed ID: 26810260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.
    Liu L; Lee MR; Kim JL; Whittington DA; Bregman H; Hua Z; Lewis RT; Martin MW; Nishimura N; Potashman M; Yang K; Yi S; Vaida KR; Epstein LF; Babij C; Fernando M; Carnahan J; Norman MH
    Bioorg Med Chem; 2016 May; 24(10):2215-34. PubMed ID: 27085672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
    Zhang Q; Wang J; Wang F; Chen X; He Y; You Q; Zhou H
    Chem Biol Drug Des; 2014 Jan; 83(1):27-36. PubMed ID: 24164966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis,
    Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Oh CH
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1534-1543. PubMed ID: 31452407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.